Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Convertible Debt (2019 - 2025)

Cytokinetics (CYTK) has disclosed Convertible Debt for 7 consecutive years, with $889.5 million as the latest value for Q3 2025.

  • Quarterly Convertible Debt rose 61.3% to $889.5 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $889.5 million through Sep 2025, up 61.3% year-over-year, with the annual reading at $549.0 million for FY2023, 0.58% up from the prior year.
  • Convertible Debt for Q3 2025 was $889.5 million at Cytokinetics, up from $554.0 million in the prior quarter.
  • The five-year high for Convertible Debt was $889.5 million in Q3 2025, with the low at $90.9 million in Q1 2021.
  • Average Convertible Debt over 5 years is $420.7 million, with a median of $546.9 million recorded in 2023.
  • The sharpest move saw Convertible Debt soared 480.48% in 2022, then rose 0.58% in 2023.
  • Over 5 years, Convertible Debt stood at $95.5 million in 2021, then surged by 471.7% to $545.8 million in 2022, then increased by 0.58% to $549.0 million in 2023, then grew by 0.45% to $551.5 million in 2024, then skyrocketed by 61.3% to $889.5 million in 2025.
  • According to Business Quant data, Convertible Debt over the past three periods came in at $889.5 million, $554.0 million, and $553.1 million for Q3 2025, Q2 2025, and Q1 2025 respectively.